KALA BIO Inc reports results for the quarter ended June 30 - Earnings Summary

• KALA BIO Inc KALA.OQ reported a quarterly adjusted loss of $1.71​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-3.16. The mean expectation of two analysts for the quarter was for a loss of $1.70 per share. Wall Street expected results to range from $-2.54 to $-1.52 per share.

• Reported revenue was zero​; analysts expected zero.

• KALA BIO Inc's reported EPS for the quarter was a loss of $1.41​.

• The company reported a quarterly loss of $11.16 million.

• KALA BIO Inc shares had risen by 50.4% this quarter and gained 3.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.8% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for KALA BIO Inc is $12.00, about 40.3% above its last closing price of $7.16

This summary was machine generated from LSEG data August 8 at 02:06 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)